Drug · DIN 02444755
DAKLINZA
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since December 3, 2019; first marketed September 8, 2015.
- Drug Identification Number (DIN)
- 02444755
- Company (DIN owner)
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Daclatasvir J05AP07
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| DACLATASVIR (DACLATASVIR DIHYDROCHLORIDE) | 60 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 13, 2015: NOC 17193New Drug Submission (NDS)
Other DINs named DAKLINZA
- DIN 02444747 · Cancelled Post Market